Cite
HARVARD Citation
Garcia‐Manero, G. et al. (n.d.). A phase 2, randomized, double‐blind, multicenter study comparing siltuximab plus best supportive care (BSC) with placebo plus BSC in anemic patients with International Prognostic Scoring System low‐ or intermediate‐1–risk myelodysplastic syndrome. American journal of hematology. 89 (9), pp. E156-E162. [Online].